Asset Details
Do you wish to reserve the book?
Outcomes of establishing a neonatal peripheral vascular access team
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Outcomes of establishing a neonatal peripheral vascular access team
Do you wish to request the book?
Outcomes of establishing a neonatal peripheral vascular access team
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Outcomes of establishing a neonatal peripheral vascular access team
2023
Overview
Correspondence to Matheus van Rens, Neonatal Intensive Care Unit, Women's Wellness and Research Center, Hamad Medical Corporation, Doha, Qatar; matheusvanrens@gmail.com Intravenous vascular access (VA) is essential in neonatal intensive care units (NICUs). Short peripheral intravenous catheters (PIVCs) are the most frequently used short-term device.1 Many unmodifiable and potentially modifiable factors affect the incidence of complications, contributing to the success or failure of therapy.2 Numerous interventions such as evidence-based care bundles, innovations in device design and manufacturer are targeted at reducing the incidence and severity of complications.3 Internationally, specialist multiprofessional teams for central venous access are widely established4 but evidence about the impacts of teams for managing peripheral intravenous access is less evident. [...]we aimed to examine the impacts of a dedicated neonatal peripheral vascular access team (NeoVAT) on key clinical and organisational quality measures of infusion therapy. [...]economic analysis to determine a fuller picture is required.Table 1 NeoVAT results Factor 2018 2019 2020 RR P value Insertion success Overall insertion success 81% 82% 96% 0.84 (0.83–0.85) <0.001 1st attempt success – 60% 68% 0.88 (0.85–0.91) <0.001 Average attempts 1.7 1.5 1.4 <0.001 Dwell time Average dwell time* 32 hours 34 hours 36 hours <0.001 PLABSI PLABSI events (n=events) 52 25 19 PLABSI rate per 1000 /days 1.68 0.78 0.55 0.47 (0.29–0.77) <0.001 Complications Failure of therapy 58.5% 55.0% 49.6% 0.85 (0.83–0.87) <0.001 Occurrence phlebitis 47.0% 41.0% 32.0% 0.68 (0.65–0.71) <0.001 PIVIE Severity Score 21 15 13 <0.001 *Dwell time calculated from date and time of insertion to date and time of removal.
